BIOMAT Database Logo BIOMAT Database Logo

Clinical value of CA125, CA19-9, CEA, CA72-4, and TPA in borderline ovarian tumor. 1996

K Tamakoshi, and F Kikkawa, and K Shibata, and K Tomoda, and N H Obata, and F Wakahara, and Y Tokuhashi, and H Ishikawa, and M Kawai, and Y Tomoda
Department of Obstetrics and Gynecology, Nagoya University School of Medicine, Japan.

Five tumor markers were analyzed clinically in 101 patients with borderline ovarian tumors who were treated by the Tokai Ovarian Tumor Study Group, an association comprising Nagoya University and its affiliated hospital, between January 1986 and December 1994. The positive rate of CA125 was 68.2% in serous tumor and 51.9% in mucinous tumor. The positive rate of CA19-9 was 51.5% in serous tumor and 44.7% in mucinous tumor. The positive rates and mean serum levels of CA125 in serous and mucinous tumor by stage had rising tendencies with an increase in each stage. The mean serum levels of CA19-9 in serous and mucinous tumor by stage had rising tendencies with an increase in each stage. CA125 and CA19-9 were useful for screening of borderline ovarian tumors. The positive rates of CEA and TPA in mucinous tumor were 32.5 and 27.3%, respectively, although none of the patients with serous tumor were positive in CEA and TPA. The positive rates and mean serum levels of CEA in mucinous tumor by stage had rising tendencies with an increase in each stage. The positive rate of CA72-4 was significantly lower than that of CA125 (P < 0.05).

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010051 Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS. Cancer of Ovary,Ovarian Cancer,Cancer of the Ovary,Neoplasms, Ovarian,Ovary Cancer,Ovary Neoplasms,Cancer, Ovarian,Cancer, Ovary,Cancers, Ovarian,Cancers, Ovary,Neoplasm, Ovarian,Neoplasm, Ovary,Neoplasms, Ovary,Ovarian Cancers,Ovarian Neoplasm,Ovary Cancers,Ovary Neoplasm
D010455 Peptides Members of the class of compounds composed of AMINO ACIDS joined together by peptide bonds between adjacent amino acids into linear, branched or cyclical structures. OLIGOPEPTIDES are composed of approximately 2-12 amino acids. Polypeptides are composed of approximately 13 or more amino acids. PROTEINS are considered to be larger versions of peptides that can form into complex structures such as ENZYMES and RECEPTORS. Peptide,Polypeptide,Polypeptides
D002272 Carcinoembryonic Antigen A glycoprotein that is secreted into the luminal surface of the epithelia in the gastrointestinal tract. It is found in the feces and pancreaticobiliary secretions and is used to monitor the response to colon cancer treatment. Antigens, CD66e,CD66e Antigen,Antigen, CD66e,Antigen, Carcinoembryonic,CD66e Antigens
D002288 Adenocarcinoma, Mucinous An adenocarcinoma producing mucin in significant amounts. (From Dorland, 27th ed) Carcinoma, Colloid,Carcinoma, Mucinous,Adenocarcinomas, Mucinous,Carcinomas, Colloid,Carcinomas, Mucinous,Colloid Carcinoma,Colloid Carcinomas,Mucinous Adenocarcinoma,Mucinous Adenocarcinomas,Mucinous Carcinoma,Mucinous Carcinomas
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths

Related Publications

K Tamakoshi, and F Kikkawa, and K Shibata, and K Tomoda, and N H Obata, and F Wakahara, and Y Tokuhashi, and H Ishikawa, and M Kawai, and Y Tomoda
Comparison of serum CA72-4, CEA, TPA, CA19-9 and CA125 levels in gastric cancer patients and correlation with recurrence.
January 2002, Hepato-gastroenterology,
K Tamakoshi, and F Kikkawa, and K Shibata, and K Tomoda, and N H Obata, and F Wakahara, and Y Tokuhashi, and H Ishikawa, and M Kawai, and Y Tomoda
Clinical evaluation of CEA, CA19-9, CA72-4 and CA125 in gastric cancer patients with neoadjuvant chemotherapy.
December 2014, World journal of surgical oncology,
K Tamakoshi, and F Kikkawa, and K Shibata, and K Tomoda, and N H Obata, and F Wakahara, and Y Tokuhashi, and H Ishikawa, and M Kawai, and Y Tomoda
Clinical value of serum tumor markers CA19-9, CA125 and CA72-4 in the diagnosis of pancreatic carcinoma.
March 2014, Molecular and clinical oncology,
K Tamakoshi, and F Kikkawa, and K Shibata, and K Tomoda, and N H Obata, and F Wakahara, and Y Tokuhashi, and H Ishikawa, and M Kawai, and Y Tomoda
[A study of localizations and serum data; four tumor markers (CA125, CA19-9, CEA and TPA) in ovarian cancers].
January 1990, Nihon Gan Chiryo Gakkai shi,
K Tamakoshi, and F Kikkawa, and K Shibata, and K Tomoda, and N H Obata, and F Wakahara, and Y Tokuhashi, and H Ishikawa, and M Kawai, and Y Tomoda
The reference intervals for CA125, CA15-3, CA19-9, CA72-4, AFP, CEA, NSE and CYFRA21-1.
January 2019, Scandinavian journal of clinical and laboratory investigation,
K Tamakoshi, and F Kikkawa, and K Shibata, and K Tomoda, and N H Obata, and F Wakahara, and Y Tokuhashi, and H Ishikawa, and M Kawai, and Y Tomoda
Clinical significance and diagnostic value of serum CEA, CA19-9 and CA72-4 in patients with gastric cancer.
August 2016, Oncotarget,
K Tamakoshi, and F Kikkawa, and K Shibata, and K Tomoda, and N H Obata, and F Wakahara, and Y Tokuhashi, and H Ishikawa, and M Kawai, and Y Tomoda
Diagnostic value of an enhanced MRI combined with serum CEA, CA19-9, CA125 and CA72-4 in the liver metastasis of colorectal cancer.
December 2022, World journal of surgical oncology,
K Tamakoshi, and F Kikkawa, and K Shibata, and K Tomoda, and N H Obata, and F Wakahara, and Y Tokuhashi, and H Ishikawa, and M Kawai, and Y Tomoda
[Clinical value of serum CEA, CA19-9, CA72-4 and CA242 in the diagnosis and prognosis of gastric cancer].
February 2012, Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery,
K Tamakoshi, and F Kikkawa, and K Shibata, and K Tomoda, and N H Obata, and F Wakahara, and Y Tokuhashi, and H Ishikawa, and M Kawai, and Y Tomoda
Clinical significance and prognostic value of CA72-4 compared with CEA and CA19-9 in patients with gastric cancer.
January 2000, Disease markers,
K Tamakoshi, and F Kikkawa, and K Shibata, and K Tomoda, and N H Obata, and F Wakahara, and Y Tokuhashi, and H Ishikawa, and M Kawai, and Y Tomoda
Evaluation of Serum CEA, CA19-9, CA72-4, CA125 and Ferritin as Diagnostic Markers and Factors of Clinical Parameters for Colorectal Cancer.
February 2018, Scientific reports,
Copied contents to your clipboard!